TABLE 4.
Best ORR by RECIST in CPI‐naïve patients
| NSCLC (N = 20) | SCCHN (N = 27) | Melanoma (N = 5) | Bladder cancer (N = 19) | Gastric cancer (N = 9) | TNBC (N = 13) | Total (N = 93) | |
|---|---|---|---|---|---|---|---|
| ORR, % (95% CI) | 15.0 (3.2–37.9) | 14.8 (4.2–33.7) | 80.0 (28.4–99.5) | 15.8 (3.4–39.6) | 0 (0.0–33.6) | 7.7 (0.2–36.0) | 16.1 (9.3–25.2) |
| CR, No. (%) | 0 | 0 | 2 (40.0) | 1 (5.3) | 0 | 0 | 3 (3.2) |
| PR, No. (%) | 3 (15.0) | 4 (14.8) | 2 (40.0) | 2 (10.5) | 0 | 1 (7.7) | 12 (12.9) |
| SD, No. (%) | 7 (35.0) | 11 (40.7) | 0 | 0 | 0 | 3 (23.1) | 21 (22.6) |
| PD, No. (%) | 7 (35.0) | 7 (25.9) | 1 (20.0) | 8 (42.1) | 6 (66.7) | 7 (53.8) | 36 (38.7) |
| NE, No. (%) | 0 | 0 | 0 | 0 | 0 | 1 (7.7) | 1 (1.1) |
| Missing, No. (%) | 3 (15.0) | 5 (18.5) | 0 | 8 (42.1) | 3 (33.3) | 1 (7.7) | 20 (21.5) |
Abbreviations: CPI, checkpoint inhibitor; CR, complete response; NE, not evaluable; NSCLC, non–small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SCCHN, squamous cell carcinoma of head and neck cancer; SD, stable disease; TNBC, triple negative breast cancer.